TNGX RSI Chart
Last 7 days
-7.6%
Last 30 days
-0.9%
Last 90 days
-38.0%
Trailing 12 Months
103.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 37.2M | 0 | 0 | 0 |
2023 | 24.9M | 33.7M | 37.5M | 36.5M |
2022 | 36.4M | 24.0M | 24.2M | 24.9M |
2021 | 18.8M | 29.9M | 31.6M | 37.0M |
2020 | 0 | 0 | 0 | 7.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 03, 2024 | mva investors, llc | sold | -456,600 | 7.61 | -60,000 | - |
May 02, 2024 | mva investors, llc | sold | -567,000 | 7.56 | -75,000 | - |
May 01, 2024 | mva investors, llc | sold | -557,250 | 7.43 | -75,000 | - |
Feb 20, 2024 | third rock ventures iv, l.p. | sold | -1,950,000 | 12.00 | -162,500 | - |
Feb 07, 2024 | barry douglas | sold | -17,087 | 12.6198 | -1,354 | general counsel |
Feb 07, 2024 | crystal adam | sold | -51,526 | 12.6198 | -4,083 | see remarks |
Feb 07, 2024 | beckman daniella | sold | -22,930 | 12.6198 | -1,817 | chief financial officer |
Feb 07, 2024 | weber barbara | sold | -56,246 | 12.6198 | -4,457 | chief executive officer |
Feb 06, 2024 | weber barbara | sold | -58,805 | 12.5626 | -4,681 | chief executive officer |
Feb 06, 2024 | beckman daniella | sold | -23,969 | 12.5626 | -1,908 | chief financial officer |
Which funds bought or sold TNGX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | AJOVista, LLC | sold off | -100 | -60,717 | - | -% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 146 | 481,164 | 974,214 | -% |
May 10, 2024 | BlackRock Inc. | reduced | -2.23 | -8,438,620 | 30,659,200 | -% |
May 10, 2024 | Covestor Ltd | reduced | -28.57 | - | - | -% |
May 10, 2024 | DIMENSIONAL FUND ADVISORS LP | added | 293 | 1,277,960 | 1,871,110 | -% |
May 10, 2024 | CREDIT SUISSE AG/ | added | 5.82 | -92,510 | 518,934 | -% |
May 10, 2024 | CITIGROUP INC | added | 2,245 | 1,439,160 | 1,519,980 | -% |
May 10, 2024 | Clear Harbor Asset Management, LLC | added | 20.26 | -7,450 | 202,430 | 0.02% |
May 10, 2024 | VANGUARD GROUP INC | added | 3.41 | -5,031,970 | 24,462,200 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 14.69 | -10,946 | 125,555 | -% |
Unveiling Tango Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Tango Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Tango Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q2 |
Revenue | 19.1% | 6,471,000 | 5,431,000 | 10,732,000 | 14,598,000 | 5,766,000 | 6,411,000 | 6,920,000 | 5,771,000 | 5,758,000 | 5,716,000 | 6,787,000 | 18,153,000 | 6,386,000 | 271,000 | 5,064,000 |
Operating Expenses | 20.5% | 48,726,000 | 40,444,500 | 36,358,000 | 37,845,000 | 36,052,000 | 36,978,000 | 36,843,000 | 30,973,000 | 31,137,000 | 27,700,000 | 26,356,000 | 22,709,000 | 18,467,000 | 18,079,000 | 13,507,000 |
S&GA Expenses | -100.0% | - | 9,105,500 | 9,209,000 | 9,174,000 | 8,013,000 | 7,887,000 | 8,099,000 | 7,232,000 | 6,807,000 | 6,066,000 | 4,433,000 | 3,630,000 | 3,467,000 | 303,433 | 2,378,000 |
R&D Expenses | 21.5% | 38,065,000 | 31,339,000 | 27,149,000 | 28,671,000 | 28,039,000 | 29,091,000 | 28,744,000 | 23,741,000 | 24,330,000 | 21,634,000 | 21,923,000 | 19,079,000 | 15,000,000 | 15,063,000 | 11,129,000 |
EBITDA Margin | -7.4% | -2.72 | -2.53 | -2.47 | -3.00 | -4.29 | -4.23 | -4.08 | -3.73 | -1.91 | -1.53 | -0.27 | -0.53 | -1.05 | -6.68 | - |
Interest Expenses | -1.7% | 2,197,000 | 2,236,000 | 1,872,000 | 1,450,000 | 1,061,000 | 591,000 | 350,000 | 297,000 | 218,000 | 196,000 | 91,000 | 104,000 | 104,000 | - | - |
Income Taxes | 207.7% | 40,000 | 13,000 | 23,000 | 64,000 | - | 51,000 | - | 3,000 | - | 177,000 | 62,000 | -21,000 | 74,000 | 3,432 | - |
Earnings Before Taxes | -23.3% | -37,874,000 | -30,716,000 | -22,240,000 | -20,646,000 | -28,008,000 | -29,009,000 | -29,050,000 | -24,855,000 | -25,208,000 | -21,869,000 | -19,528,000 | -4,514,000 | -12,032,000 | 26,685,818 | -8,392,000 |
EBT Margin | -7.6% | -2.99 | -2.78 | -2.66 | -3.17 | -4.46 | -4.35 | -4.18 | -3.81 | -1.95 | -1.56 | -0.30 | -0.56 | -1.09 | -6.79 | - |
Net Income | -23.2% | -37,914,000 | -30,763,000 | -22,263,000 | -20,710,000 | -28,008,000 | -29,060,000 | -29,050,000 | -24,858,000 | -25,208,000 | -22,046,000 | -19,590,000 | -4,493,000 | -12,106,000 | -8,864,000 | -8,392,000 |
Net Income Margin | -7.7% | -3.00 | -2.79 | -2.67 | -3.17 | -4.46 | -4.35 | -4.19 | -3.82 | -1.96 | -1.57 | -1.43 | -1.75 | -2.99 | -6.79 | - |
Free Cashflow | -37.4% | -38,052,000 | -27,693,000 | -31,151,000 | -25,137,000 | -35,527,000 | -29,307,000 | -22,890,000 | -33,349,000 | -31,226,000 | -17,598,000 | -22,268,000 | -7,720,000 | -13,778,000 | -9,606,071 | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | 0.9% | 406 | 403 | 428 | 379 | 404 | 436 | 464 | 448 | 472 | 500 | 530 | 217 | 168 | 207 | 168 | 56.00 |
Current Assets | 1.6% | 352 | 347 | 371 | 321 | 343 | 375 | 402 | 436 | 461 | 492 | 516 | 202 | 1.00 | 194 | 2.00 | 42.00 |
Cash Equivalents | -4.0% | 64.00 | 66.00 | 59.00 | 66.00 | 57.00 | 60.00 | 100 | 105 | 100 | 143 | 205 | 51.00 | 1.00 | 28.00 | 2.00 | 23.00 |
Net PPE | -3.9% | 10.00 | 10.00 | 10.00 | 11.00 | 11.00 | 11.00 | 11.00 | 8.00 | 7.00 | 5.00 | 5.00 | 4.00 | - | 4.00 | - | 3.00 |
Liabilities | -5.1% | 142 | 149 | 152 | 166 | 177 | 187 | 191 | 150 | 151 | 155 | 165 | 162 | 166 | 169 | 6.00 | 48.00 |
Current Liabilities | -6.9% | 43.00 | 46.00 | 43.00 | 54.00 | 54.00 | 56.00 | 51.00 | 45.00 | 39.00 | 41.00 | 42.00 | 37.00 | 0.00 | 41.00 | 0.00 | 26.00 |
Shareholder's Equity | 4.5% | 264 | 253 | 277 | 213 | 227 | 249 | 273 | 299 | 320 | 345 | 365 | 55.00 | 58.00 | 39.00 | 47.00 | 8.00 |
Retained Earnings | -10.2% | -409 | -371 | -340 | -318 | -297 | -269 | -240 | -211 | -186 | -161 | -139 | -119 | -0.36 | -103 | -0.05 | -51.13 |
Additional Paid-In Capital | 8.0% | 674 | 624 | 618 | 533 | 527 | 523 | 518 | 514 | 510 | 507 | 505 | 8.00 | 5.00 | 142 | 5.00 | 3.00 |
Shares Outstanding | 4.4% | 107 | 102 | 102 | 88.00 | 88.00 | 88.00 | 88.00 | 88.00 | 88.00 | 88.00 | 53.00 | 49.00 | 42.00 | 40.00 | - | - |
Float | - | - | - | - | 177 | - | - | - | 302 | - | - | - | 190 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | -37.8% | -37,857 | -27,467 | -31,135 | -24,473 | -34,907 | -28,266 | -19,611 | -31,538 | -29,665 | -16,902 | -21,494 | -7,518 | -13,613 | -9,150 | -89.28 | - | - |
Share Based Compensation | 37.7% | 6,719 | 4,879 | 4,860 | 5,121 | 4,219 | 3,785 | 3,815 | 3,425 | 3,205 | 2,257 | 3,430 | 1,196 | 950 | 531 | 418 | - | - |
Cashflow From Investing | -133.1% | -11,203 | 33,852 | -56,664 | 32,687 | 31,551 | -12,605 | 15,228 | 35,493 | -11,717 | -45,207 | -152,214 | -6,625 | 20,612 | -29,605 | -166,750 | - | - |
Cashflow From Financing | 2829.9% | 42,982 | 1,467 | 80,280 | 586 | 73.00 | 527 | 113 | 718 | 257 | -120 | 327,780 | -746 | 30,411 | -30.50 | 168,392 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Collaboration revenue | $ 6,471 | $ 5,766 |
Operating expenses: | ||
Research and development | 38,065 | 28,039 |
General and administrative | 10,661 | 8,013 |
Total operating expenses | 48,726 | 36,052 |
Loss from operations | (42,255) | (30,286) |
Other income: | ||
Interest income | 2,197 | 1,061 |
Other income, net | 2,184 | 1,217 |
Total other income, net | 4,381 | 2,278 |
Loss before income taxes | (37,874) | (28,008) |
Provision for income taxes | (40) | 0 |
Net loss | $ (37,914) | $ (28,008) |
Net loss per common share - basic | $ (0.35) | $ (0.32) |
Net loss per common share - diluted | $ (0.35) | $ (0.32) |
Weighted average number of common shares outstanding - basic | 108,171,463 | 88,193,917 |
Weighted average number of common shares outstanding - diluted | 108,171,463 | 88,193,917 |
Net loss | $ (37,914) | $ (28,008) |
Other comprehensive (loss) income: | ||
Unrealized (loss) gain on marketable securities | (443) | 1,504 |
Comprehensive loss | $ (38,357) | $ (26,504) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 61,163 | $ 66,385 |
Marketable securities | 282,436 | 270,500 |
Restricted cash | 856 | |
Prepaid expenses and other current assets | 8,437 | 8,797 |
Total current assets | 352,036 | 346,538 |
Property and equipment, net | 9,522 | 9,908 |
Operating lease right-of-use assets | 42,086 | 43,508 |
Restricted cash, net of current portion | 2,567 | 2,567 |
Other assets | 11 | 46 |
Total assets | 406,222 | 402,567 |
Current liabilities: | ||
Accounts payable | 3,898 | 2,785 |
Accrued expenses and other current liabilities | 13,755 | 15,401 |
Operating lease liabilities | 2,066 | 2,082 |
Deferred revenue | 23,070 | 25,670 |
Total current liabilities | 42,789 | 45,938 |
Operating lease liabilities, net of current portion | 36,169 | 36,838 |
Deferred revenue, net of current portion | 62,812 | 66,683 |
Total liabilities | 141,770 | 149,459 |
Commitments and contingencies (Note 7) | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | ||
Stockholders' equity: | ||
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 106,730,785 and 102,202,759 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 107 | 102 |
Additional paid-in capital | 673,772 | 624,076 |
Accumulated other comprehensive (loss) income | (257) | 186 |
Accumulated deficit | (409,170) | (371,256) |
Total stockholders' equity | 264,452 | 253,108 |
Total liabilities and stockholders' equity | $ 406,222 | $ 402,567 |